Medscape InDiscussion: Multiple Sclerosis

About Medscape InDiscussion: Multiple Sclerosis

Listen to Medscape InDiscussion: Multiple Sclerosis, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977030). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Publisher

Medscape

Category

health & fitness · science

Language

en

Explicit

No

First episode

5 Oct 2022

Latest episode

20 Nov 2025

Latest episodes

12 episodes in the feed.

1. 

   20 Nov 2025

   S2 Episode 6: Can Fluid Biomarkers Predict MS Progression?

   Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the evolving science behind these powerful biomarkers. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002608. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Fluid Biomarkers in Multiple Sclerosis: From Current to Future Applications https://pubmed.ncbi.nlm.nih.gov/39444698/ National Hospital for Neurology and Neurosurgery https://www.uclh.nhs.uk/our-services/our-hospitals/national-hospital-neurology-and-neurosurgery Neurofilament Biophysics: From Structure to Biomechanics https://pubmed.ncbi.nlm.nih.gov/38598299/ Glymphatic System: An Emerging Therapeutic Approach for Neurological Disorders https://pubmed.ncbi.nlm.nih.gov/37485040/ Axonal Transection in the Lesions of Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/9445407/ The Combination of CSF Neurofilament Light Chain and Glial Fibrillary Acidic Protein Improves the Prediction of Long-Term Confirmed Disability Worsening in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39587121/ Amit Bar-Or, MD https://www.med.upenn.edu/apps/faculty/index.php/g324/p8937426 Anxiety, Depression, and Expanded Disability Status Scale Independently Predict the Perception of Disability in Persons With Multiple Sclerosis: A Cross-Sectional Study https://pubmed.ncbi.nlm.nih.gov/39839740/ Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria https://pubmed.ncbi.nlm.nih.gov/40975101/ Radiologically Isolated Syndrome: A 6-Year Follow-Up Study in Chile https://pubmed.ncbi.nlm.nih.gov/40120160/ Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights Into the Disease Pathophysiology, Diagnosis and Management https://pubmed.ncbi.nlm.nih.gov/33374173/

2. 

   21 Oct 2025

   S2 Episode 5: Can Imaging Biomarker Breakthroughs Help Us See MS More Clearly?

   How can imaging biomarkers enhance our understanding of MS? Dr Anne Cross and Dr Matthew Brier examine MRI advancements that provide new insights into diagnosis, progression, and treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002607. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Emerging MRI Biomarkers for the Diagnosis of Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39511991/ Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38079177/ Biomarkers for Diagnosis and Prognosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: Review Article https://pubmed.ncbi.nlm.nih.gov/40547008/ Update on Neuromyelitis Optica Spectrum Disorder https://pmc.ncbi.nlm.nih.gov/articles/PMC7771018/ Sjogren Syndrome https://emedicine.medscape.com/article/332125-overview Detection of Multiple Sclerosis Lesions by Susceptibility-Weighted Imaging: A Systematic Review and Meta-Analyses https://pubmed.ncbi.nlm.nih.gov/39406601/ The Central Vein Sign on T2*-Weighted Images as a Diagnostic Tool in Multiple Sclerosis: A Systematic Review and Meta-Analysis Using Individual Patient Data https://pubmed.ncbi.nlm.nih.gov/31796822/ Paramagnetic Rim Lesions Are Highly Specific for Multiple Sclerosis in Real-World Data https://pubmed.ncbi.nlm.nih.gov/39371137/ Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics https://pubmed.ncbi.nlm.nih.gov/30385472/ Slowly Expanding Lesions Are Associated With Disease Activity and Gray Matter Loss in Relapse-Onset Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39390692/ TSPO PET in Multiple Sclerosis: Emerging Insights Into Pathophysiology, Prognosis, and Treatment Monitoring https://pubmed.ncbi.nlm.nih.gov/40450829/ An Update on the Use of Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Relapsing Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/36946625/

3. 

   18 Sept 2025

   S2 Episode 4: Should Platform Therapies Remain First-Line in MS?

   Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared decision-making for optimal patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002606. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Interferon Beta and Glatiramer Acetate Therapy https://pubmed.ncbi.nlm.nih.gov/23264098/ Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) https://www.clinicaltrials.gov/study/NCT03500328 Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020 https://pubmed.ncbi.nlm.nih.gov/37428482/ What We Learned From the History of Multiple Sclerosis Measurement: Expanded Disability Status Scale https://pubmed.ncbi.nlm.nih.gov/30692861/ The Multiple Sclerosis Functional Composite Measure (MSFC): An Integrated Approach to MS Clinical Outcome Assessment. National MS Society Clinical Outcomes Assessment Task Force https://pubmed.ncbi.nlm.nih.gov/10467383/ Long-term Efficacy and Safety of Alemtuzumab in Participants With Highly Active MS: TOPAZ Clinical Trial and Interim Analysis of TREAT-MS Real-World Study https://pubmed.ncbi.nlm.nih.gov/39935588/ Imaging Outcome Measures for Progressive Multiple Sclerosis Trials https://pubmed.ncbi.nlm.nih.gov/29041865/ Current Use of Fluid Biomarkers as Outcome Measures in Multiple Sclerosis (MS): A Review of Ongoing Pharmacological Clinical Trials https://pubmed.ncbi.nlm.nih.gov/38117403/ Patient-reported Disability Progression Outcomes Among Patients With Multiple Sclerosis: Results of an Outcomes-Based Agreement https://pubmed.ncbi.nlm.nih.gov/39471272/ Insights for Healthcare Providers on Shared Decision-making in Multiple Sclerosis: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/38180727/ Practice Guideline Update Summary: Vaccine-Preventable Infections and Immunization in Multiple Sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology https://pubmed.ncbi.nlm.nih.gov/31462584/

4. 

   20 Aug 2025

   S2 Episode 3: Progress in Progressive MS: BTK Inhibitors and the HERCULES Study

   Can BTK inhibitors finally move the needle in progressive MS? Dr Robert Fox joins Dr Anne Cross to unpack the results of the HERCULES trial and explore what’s next. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002605. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202696/ Bruton Tyrosine Kinase Inhibitors in Multiple Sclerosis: Evidence and Expectations https://pubmed.ncbi.nlm.nih.gov/38533819/ Safety and Efficacy of Tolebrutinib, an Oral Brain-Penetrant BTK Inhibitor, in Relapsing Multiple Sclerosis: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/34418400/ Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis https://clinicaltrials.gov/study/NCT03996291 Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202623/ Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS) https://clinicaltrials.gov/study/NCT04458051 Fenebrutinib, a Bruton's Tyrosine Kinase Inhibitor, Blocks Distinct Human Microglial Signaling Pathways https://pubmed.ncbi.nlm.nih.gov/39465429/ Rilzabrutinib, a Reversible Covalent Bruton's Tyrosine Kinase Inhibitor: Absorption, Metabolism, Excretion, and Absolute Bioavailability in Healthy Participants https://pubmed.ncbi.nlm.nih.gov/37060187/ Orelabrutinib: First Approval https://pubmed.ncbi.nlm.nih.gov/33704654/ Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38648580/ Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/30157388/

5. 

   16 Jul 2025

   S2 Episode 2: The Exercise Prescription for MS Just Got Stronger

6. 

   16 Jul 2025

   S2 Episode 1: Caught Off Guard? Menopause in MS Deserves Better

   Join Drs Anne Cross and Riley Bove as they discuss menopause in multiple sclerosis, including overlapping symptoms, hormone therapy, and why this transition shouldn't catch anyone off guard. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002583. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Hormonal Therapies in Multiple Sclerosis: A Review of Clinical Data https://pubmed.ncbi.nlm.nih.gov/38102502/ The 2022 Hormone Therapy Position Statement of The North American Menopause Society https://pubmed.ncbi.nlm.nih.gov/35797481/ Age-Specific Effects of Hormone Therapy Use on Overall Mortality and Ischemic Heart Disease Mortality Among Women in the California Teachers Study https://pubmed.ncbi.nlm.nih.gov/20881652/ Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT https://pubmed.ncbi.nlm.nih.gov/36734148/ Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/12117397/ Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review https://pubmed.ncbi.nlm.nih.gov/33815241/ Uhthoff's Phenomenon in Multiple Sclerosis and Neuromyelitis Optica https://pubmed.ncbi.nlm.nih.gov/25195501/ Molecular Basis of Klotho: From Gene to Function in Aging https://pubmed.ncbi.nlm.nih.gov/25695404/ Re-WRAP (Remyelination for Women at Risk of Axonal Loss and Progression): A Phase II Randomized Placebo-Controlled Delayed-Start Trial of Bazedoxifene for Myelin Repair in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/37739167/ Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial https://pubmed.ncbi.nlm.nih.gov/29029896/

7. 

   2 Feb 2023

   Reproductive Rights, Maternal Health, and Menopause: Women and MS

   Most MS patients are women, often diagnosed during their childbearing years. Drs Anne Cross and Riley Bove discuss maternal health, IVF, birth control, and menopause when living with MS. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977036). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Teriflunomide (Rx) https://reference.medscape.com/drug/aubagio-teriflunomide-999771 Sphingosine 1-Phosphate Receptor Modulators https://reference.medscape.com/drugs/sphingosine-1-phosphate-receptor-modulators Natalizumab Prescribing Information https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902174/ Perinatal Depression and Anxiety in Women With Multiple Sclerosis https://n.neurology.org/content/96/23/e2789 Risk Factors for Peripartum Depression in Women With Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/13524585211041108 Long-Acting Reversible Contraception: Comparing Methods https://www.medscape.com/viewarticle/857253 Neonatal and Delivery Outcomes in Women With Multiple Sclerosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625744/ Familial Risk of Early- and Late-Onset Multiple Sclerosis: A Swedish Nationwide Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373346

8. 

   4 Jan 2023

   Advancing the Science: MIND Diet, Lifestyle, and Multiple Sclerosis

   Drs Cross and Katz Sand discuss the science behind diet and lifestyle interventions for patients living with MS. Learn about studies underway to help clinicians better incorporate diet and lifestyle recommendations into practice. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977035). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Randomized-Controlled Trial of a Modified Mediterranean Dietary Program for Multiple Sclerosis: A Pilot Study https://www.msard-journal.com/article/S2211-0348(19)30383-9/fulltext Mediterranean Diet Is Linked to Less Objective Disability in Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/13524585221127414 Dietary Factors and MRI Metrics in Early Multiple Sclerosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515355/ Multiple Sclerosis Functional Composite (MSFC) https://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-MS-Researchers/Research-Tools/Clinical-Study-Measures/Multiple-Sclerosis-Functional-Composite-(MSFC) Kurtzke Expanded Disability Status Scale https://emedicine.medscape.com/article/2172461-overview How to Incorporate Diet Into Multiple Sclerosis Care https://www.medscape.com/viewarticle/972812

9. 

   1 Dec 2022

   Can Cannabis Help Patients With MS?

   Drs Cross and Bainbridge discuss cannabis, safety issues, drug-drug interactions, potential liver toxicity, tolerance, and possible dependency for people living with MS. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977034). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Cannabinoids in Medicine: Limitless Hope or Hype? https://www.medscape.com/viewarticle/973874 Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312634/ Sativex Prescribing Information https://www.tga.gov.au/sites/default/files/auspar-nabiximols-130927-pi.pdf Epidiolex Prescribing Information https://pp.jazzpharma.com/pi/epidiolex.en.USPI.pdf Cannabinoid Poisoning Workup https://emedicine.medscape.com/article/833828-workup Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate" https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2021.21111126 Cannabinoid Hyperemesis Syndrome https://www.ncbi.nlm.nih.gov/books/NBK549915/ Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants With Multiple Sclerosis Spasticity https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-top-line-results-phase-3-trial

10. 

    3 Nov 2022

    Should We Discontinue Medications in Older Patients With Multiple Sclerosis?

    As patients with MS in the United States get older, questions about therapies shift from treatment to discontinuation. Drs Cross and Corboy discuss the DISCOMS trial to address these questions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977033). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources The Prevalence of MS in the United States https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442006/pdf/NEUROLOGY2018886077.pdf Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) (DISCOMS) https://clinicaltrials.gov/ct2/show/NCT03073603 Stopping Disease-Modifying Therapy in Relapsing and Progressive Multiple Sclerosis https://journals.lww.com/co-neurology/Abstract/2021/08000/Stopping_disease_modifying_therapy_in_relapsing.18.aspx Discontinuation of Disease-Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study https://www.ninds.nih.gov/health-information/clinical-trials/discontinuation-disease-modifying-therapies-dmts-multiple-sclerosis-ms-extension-discoms-study North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) https://www.narcrms.org/ How MS Disability Is Measured https://www.webmd.com/multiple-sclerosis/disability-measured Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010264/pdf/fneur-12-647811.pdf Natalizumab Discontinuation in a Dutch Real-world Cohort https://www.sciencedirect.com/science/article/abs/pii/S2211034821002418 Factors Associated With Fingolimod Rebound: A Single Center Real-life Experience https://www.sciencedirect.com/science/article/abs/pii/S2211034821005459 Serious Safety Events in Rituximab-Treated Multiple Sclerosis and Related Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480911/

11. 

    5 Oct 2022

    COVID-19 and MS Patients: Where Do We Go From Here?

    Agoraphobia, online yoga, pregnancy, and vaccines are all on the table as Drs Anne Cross and Scott Newsome discuss the COVID-19 pandemic and how it affects their patients with MS. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977031). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Coronavirus Disease 2019 (COVID-19) https://emedicine.medscape.com/article/2500114-overview Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview COViMS Registry https://www.covims.org/ An Italian Programme for COVID-19 Infection in Multiple Sclerosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191287/ Paxlovid Emergency Use Authorization https://labeling.pfizer.com/ShowLabeling.aspx?id=16474 Bebtelovimab Fact Sheet for Healthcare Providers https://www.fda.gov/media/156152/download Remdesivir Prescribing Information https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf Evusheld Fact Sheet for Healthcare Providers https://www.fda.gov/media/154701/download New Diagnosis of Multiple Sclerosis in the Setting of mRNA COVID-19 Vaccine Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656147/ COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407145/ Neuro-Ophthalmologic Manifestations of Multiple Sclerosis https://emedicine.medscape.com/article/1214270-overview

12. 

    5 Oct 2022

    In the Busy MS Clinic: Diagnosing and Treating Cognitive Dysfunction

    Drs Anne Cross and Lauren Krupp talk about the latest research and their real-life experience identifying and treating cognitive dysfunction in patients with MS in the busy clinic setting. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977030). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview A Preliminary Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Tool in an Irish Population With Multiple Sclerosis (MS) https://www.msard-journal.com/article/S2211-0348(15)00111-X/fulltext Digital Cognitive Testing Uncovers Hidden Impairment in MS https://www.medscape.com/viewarticle/892482 MIND Diet Adherence Might Be Associated With a Reduced Odds of Multiple Sclerosis: Results From a Case-Control Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857348/ Pediatric Multiple Sclerosis: Cognition and Mood https://n.neurology.org/content/87/9_Supplement_2/S82.long Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229753/ Cognitive Dysfunction in Early-Onset Multiple Sclerosis https://jamanetwork.com/journals/jamaneurology/fullarticle/780539

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

4 ratings

Podcast Authority Score: 13 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

13

Social presence

0

YouTube

0

Engagement

32

Contact Medscape InDiscussion: Multiple Sclerosis

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.